PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2023.00182023292510-512Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”Chia-Ming Chu, Yun-Fan Liawhttp://e-cmh.org/upload/pdf/cmh-2023-0018.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0018, http://e-cmh.org/upload/pdf/cmh-2023-0018.pdf
Clinical and Molecular Hepatology10.3350/cmh.2023.00442023292513-515Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”Jeong-Ju Yoo, Sang Gyune Kimhttp://e-cmh.org/upload/pdf/cmh-2023-0044.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0044, http://e-cmh.org/upload/pdf/cmh-2023-0044.pdf
Clinical and Molecular Hepatology10.3350/cmh.2022.03222023292482-495Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phaseJeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kimhttp://e-cmh.org/upload/pdf/cmh-2022-0322.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0322, http://e-cmh.org/upload/pdf/cmh-2022-0322.pdf
Journal of Hepatology10.1016/s0168-8278(23)03222-1202378S1107Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tolerant phaseZeyuan Yang, Ramsey C. Cheung, Robert Wonghttps://api.elsevier.com/content/article/PII:S0168827823032221?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827823032221?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(87)80353-719875S136Clinical, serological and histologic follow-up of chronic HBV and HDV hepatitishttps://api.elsevier.com/content/article/PII:S0168827887803537?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827887803537?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(23)03204-x202378S1094-S1095Lower HBV DNA levels is associated more severe liver fibrosis in chronic hepatitis B with serological immune-tolerant phaseJian Wang, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Xiaomin Yan, Weihua Wu, Weimao Ding, Chuanwu Zhu, Jie Li, Rui Huang, Chao Wuhttps://api.elsevier.com/content/article/PII:S016882782303204X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S016882782303204X?httpAccept=text/plain
Journal of Hepatology10.1016/0168-8278(90)90191-s199011S161Long-term histologic outcome of chronic posttransfusion NANB hepatitis evaluated by a scoring systemL Mattsson, O Weiland, H Ghumannhttps://api.elsevier.com/content/article/PII:016882789090191S?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:016882789090191S?httpAccept=text/plain
Hepatology Research10.1016/s1386-6346(00)00094-22001192131-143Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis CY Momosakahttps://api.elsevier.com/content/article/PII:S1386-6346(00)00094-2?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1386-6346(00)00094-2?httpAccept=text/plain
Focus on Alternative and Complementary Therapies10.1111/fct.12101201419296-97Potential treatment for chronic hepatitis B carriers at immune tolerant phaseR Guohttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ffct.12101, http://onlinelibrary.wiley.com/wol1/doi/10.1111/fct.12101/fullpdf
Hepatology10.1053/jhep.2003.503292003382493-502Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort studyF Imazekihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50329, https://onlinelibrary.wiley.com/doi/full/10.1053/jhep.2003.50329